Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Gastrointestinal tumours, non colorectal

4391 - TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer


21 Oct 2018


Proffered paper session - Gastrointestinal tumours, non colorectal


Cytotoxic Therapy

Tumour Site

Gastric Cancer


Hendrik-Tobias Arkenau


H. Arkenau1, J. Tabernero2, K. Shitara3, M. Dvorkin4, W. Mansoor5, A. Prokharau6, M. Alsina2, M. Ghidini7, C. Faustino8, V. Gorbunova9, E.A. Zhavrid10, K. Nishikawa11, A. Hosokawa12, D. Ganea13, Ş. Yalçın14, G.D. Beretta15, R.E. Winkler16, L. Makris17, T. Doi18, D.H. Ilson19

Author affiliations

  • 1 Scri, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
  • 2 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 3 Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Kashiwa-city, Chiba/JP
  • 4 Oncology, Omsk Regional Clinical Centre of Oncology, 644013 - Omsk, Omsk Region/RU
  • 5 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 6 Oncology, Minsk City Clinical Oncology Dispensary, 220013 - Minsk/BY
  • 7 Oncology, Azienda Ospedaliera di Cremona, 26100 - Cremona/IT
  • 8 Oncology, Instituto Português de Oncologia do Porto, 4200-072 - Porto/PT
  • 9 Oncology, N.N.Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 10 Oncology, Alexandrov National Cancer Centre of Belarus, 223040 - Minsk/BY
  • 11 Surgery, Osaka National Hospital, 565-0871 - Osaka/JP
  • 12 Medical Oncology, University of Toyoma, 930-8588 - Toyoma/JP
  • 13 Oncology, Spitalul Judetean de Urgenta Sfantul Ioan cel Nou Suceava, 720262 - Suceva/RO
  • 14 Medical Oncology, Hacettepe University, 06532 - Ankara/TR
  • 15 Oncology, Humanitas Gavazzeni, 24125 - Bergamo/IT
  • 16 Clinical Development, Taiho Oncology, Inc., 08540 - Princeton/US
  • 17 Statistics, Stathmi Inc., 18938-9239 - New Hope/US
  • 18 Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 19 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4391


Trifluridine/tipiracil (FTD/TPI) demonstrated promising efficacy and was well tolerated in a Japanese phase 2 trial of pretreated patients (pts) with advanced gastric cancer. TAGS (NCT02500043) was conducted to confirm these findings.


This global phase 3 study enrolled pts aged ≥18 y with histologically confirmed, non-resectable metastatic gastric cancer (mGC), Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1, and ≥2 prior chemotherapy regimens. Pts were randomised 2:1 to receive FTD/TPI (35 mg/m2 BID on days 1–5 and 8–12 of each 28-day cycle) or placebo, plus best supportive care.


Between Feb 2016 and Jan 2018, 507 pts were randomised to receive FTD/TPI (n=337) or placebo (n=170). Baseline pt characteristics were balanced across treatment groups; 317 pts (63%) had received ≥3 lines of prior systemic therapy. At data cut-off (31 Mar 2018), median follow-up was 10.7 mo and the primary endpoint was met: the risk of death was lower with FTD/TPI vs placebo (HR 0.69; 95% CI 0.56–0.85; P=0.0003; median overall survival [OS] 5.7 vs 3.6 mo). Subgroup OS analyses favored FTD/TPI over placebo in most prespecified subgroups (eg, ethnicity, geographic region, ECOG PS, number of prior regimens). FTD/TPI vs placebo was associated with a lower risk of disease progression or death (HR 0.57; 95% CI 0.47–0.70; P<0.0001). Progression-free survival was longer with FTD/TPI vs placebo in all subgroups. Pts in the FTD/TPI group had a higher disease control rate (44% vs 14%; P<0.0001) and lower risk of ECOG PS deterioration to ≥2 (HR 0.69; 95% CI 0.56–0.85; P=0.0005). Grade ≥3 any-cause adverse events (AEs) were reported in 267/335 (80%) FTD/TPI-treated pts and 97/168 (58%) placebo-treated pts. Any-grade AEs led to dosing delay/dose reduction in 195 (58%) FTD/TPI-treated and 37 (22%) placebo-treated pts. Dosing delays were used more often than dose reduction to manage AEs. One treatment-related death was reported in each treatment group. No new safety signals were noted.


In this phase 3 study, FTD/TPI provided clinically meaningful and statistically significant prolongation in OS (31% reduction in risk of death) and was well tolerated in pts with heavily pretreated mGC.

Clinical trial identification


Editorial Acknowledgement

Medical writing and editorial assistance were provided by Mark Palangio, Wendy Sacks, and Lilly Ostrovsky of Scientific Connexions, funded by Taiho Oncology, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.